[시장보고서]혈뇨 치료 시장 규모, 점유율 및 동향 분석 보고서 : 치료 유형별, 유형별, 지역별, 부문 예측(2025-2033년)

혈뇨 치료 시장 규모, 점유율 및 동향 분석 보고서 : 치료 유형별, 유형별, 지역별, 부문 예측(2025-2033년)

Hematuria Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Pharmacotherapy, Procedural / Interventional Therapies, Adjunctive / Supportive Therapies), By Type, By Region, And Segment Forecasts, 2025 - 2033

상품코드 : 1869869

리서치사 : Grand View Research

발행일 : 2025년 10월

페이지 정보 : 영문 100 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,879,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,371,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 13,356,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

혈뇨 치료 시장 요약

세계의 혈뇨 치료 시장 규모는 2024년 10억 8,730만 달러로 평가되었고, 2033년까지 14억 2,690만 달러에 이를 것으로 예측됩니다.

2025-2033년의 CAGR은 3.1%를 나타낼 전망입니다. 본 시장은 비뇨기과 치료에 의해 주도되며, 고령 인구 증가와 함께 재발성 요로 감염, 방광암, 요로결석증의 유병률 증가로 지속됩니다.

혈뇨는 방광암의 가장 흔하고 중요한 초기 임상 징후로, 방광암은 광범위한 진단 및 치료 자원이 필요한 고부담 질환입니다. 또한 전 세계적으로 방광암 발생률이 증가함에 따라 시장 전체 성장이 촉진될 것으로 예상됩니다. 미국에서는 미국암협회(ACS)가 2025년 신규 환자 수를 8만 4,870명으로 예측하며, 이는 안정적인 발병률과 진단용 방광경 검사에 대한 지속적인 의존도를 반영합니다. 대부분의 방광암은 반복적인 방광경 검사와 위험도 기반 방광내 치료를 통한 지속적인 모니터링이 필요하므로, 증가하는 환자 수가 혈뇨 치료 산업을 견인하고 있습니다.

또한 요로감염(UTI) 발생률 증가로 간헐적 혈뇨 증상과 경험적 항생제 사용이 늘어나 긴급 평가 수요를 촉진하고 신속한 현장진단(POCT)에 대한 압박을 가중시키고 있습니다. 새로운 신속 진단법은 병원체 확인 시간을 단축시켜 진단까지 소요되는 시간을 줄임으로써 혈뇨 치료 경로에 직접적인 영향을 미치고 있습니다.

요로결석증 유병률과 증상성 결석 사건은 가시적 혈뇨의 중요한 비종양성 원인이며, 종종 결정적 내시경 요로 치료(내시경 요관경 검사(URS), 경피적 신경관 절제술(PCNL)) 또는 영상학적 분류가 필요합니다. 일부 연령 표준화 비율은 감소했지만, 절대 환자 수와 신규 발병 건수는 많은 지역에서 증가했습니다. 이 질환은 증상과 높은 재발 가능성으로 특징지어지며, 특히 20-54세 개인에게 영향을 미치며 의료 시스템에 상당한 부담을 초래하고 있습니다. 이는 많은 지역에서 결석 질환의 상당한 연령 표준화 발생률과 증가하는 비율을 나타내며, 응급 및 선택적 시술 건수를 증가시킵니다. 진단적 방광경 검사는 여전히 가장 빈번하게 시행되는 비뇨기과 시술 중 하나이므로, 증가하는 결석 및 혈뇨 의뢰가 산업을 주도하고 있습니다.

지역별 시장 대시보드
지역별 시장 점유율 분석(2024년, 2030년)
지역별 혈뇨 치료 시장 : 주요 포인트
북미
- 미국
- 캐나다
유럽
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 한국
- 호주
- 태국
라틴아메리카
- 브라질
- 멕시코
- 아르헨티나
중동 및 아프리카
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트

제7장 경쟁 구도

주요 시장 진출기업의 최근 동향 및 영향 분석
기업/경쟁의 분류
벤더 상황
기업 프로파일
- AstraZeneca
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- Johnson &Johnson and its affiliates
- Merck &Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd.

HBR

영문 목차

영문목차

Hematuria Treatment Market Summary

The global hematuria treatment market size was estimated at USD 1,087.3 million in 2024 and is projected to reach USD 1,426.9 million by 2033, growing at a CAGR of 3.1% from 2025 to 2033. The market is driven by urological care and sustained by the growing prevalence of recurrent urinary tract infections, bladder cancer, and urolithiasis, alongside an expanding geriatric population.

Hematuria is the most common and vital early clinical sign for bladder cancer, which is a high-burden disease that requires extensive diagnostic and therapeutic resources. Moreover, the increasing incidence of bladder cancer cases globally is expected to drive the overall market growth. In the U.S., the American Cancer Society projects 84,870 new cases in 2025, reflecting stable incidence and continued reliance on diagnostic cystoscopy. Given that most bladder cancers require ongoing surveillance through repeated cystoscopy and risk-adapted intravesical therapy, rising case volumes drive the hematuria treatment industry.

Furthermore, rising urinary tract infection (UTI) incidence increases episodic hematuria presentations and empirical antibiotic use, which drives urgent evaluation demand and creates pressure for faster, point-of-care diagnostics. New rapid diagnostics have shortened pathogen identification, directly affecting hematuria treatment pathways by shortening time-to-diagnosis.

Urolithiasis prevalence and symptomatic stone events are important non-neoplastic causes of visible hematuria and often require definitive endourologic care (URS, PCNL) or imaging triage. Although some age-standardised rates have declined, absolute case counts, and new presentations have risen in many regions. It is characterized by symptoms and a high likelihood of recurrence and has created a considerable burden on the healthcare system, especially affecting individuals aged 20 to 54. This indicates substantial age-standardized incidence of stone disease and rising rates in many regions, which raises emergency and elective procedure volumes. Diagnostic cystoscopy remains among the most frequently performed urology procedures, so rising stone and hematuria referrals drive the industry.

Global Hematuria Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global hematuria treatment market report based on treatment type, type, and region:

Treatment Type Outlook (Revenue, USD Million, 2021 - 2033)
Pharmacotherapy
Procedural / Interventional Therapies
Adjunctive / Supportive Therapies
Type Outlook (Revenue, USD Million, 2021 - 2033)
Branded
Generic
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Thailand
Latin America
- Brazil
- Mexico
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Treatment type
- 1.2.2. Type
- 1.2.3. Regional scope
- 1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Treatment type outlook
- 2.2.2. Type outlook
- 2.2.3. Regional outlook
2.3. Competitive Insights

Chapter 3. Hematuria Treatment Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.2. Market restraint analysis
3.3. Hematuria Treatment Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
  - 3.3.1.1. Supplier power
  - 3.3.1.2. Buyer power
  - 3.3.1.3. Substitution threat
  - 3.3.1.4. Threat of new entrant
  - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
  - 3.3.2.1. Political landscape
  - 3.3.2.2. Technological landscape
  - 3.3.2.3. Economic landscape

Chapter 4. Hematuria Treatment Market: Treatment Type Estimates & Trend Analysis

4.1. Treatment Type Segment Dashboard
4.2. Hematuria Treatment Market: Treatment Type Movement Analysis
4.3. Global Hematuria Treatment Market Size & Trend Analysis, by Treatment Type, 2021 to 2033 (USD Million)
- 4.3.1. Pharmacotherapy
  - 4.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 4.3.2. Procedural / Interventional Therapies
  - 4.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 4.3.3. Adjunctive / Supportive Therapies
  - 4.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Hematuria Treatment Market: Type Estimates & Trend Analysis

5.1. Type Segment Dashboard
5.2. Hematuria Treatment Market: Type Movement Analysis
5.3. Global Hematuria Treatment Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
- 5.3.1. Branded
  - 5.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 5.3.2. Generic
  - 5.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Hematuria Treatment Market: Regional Estimates & Trend Analysis

6.1. Regional Market Dashboard
6.2. Regional Market Share Analysis, 2024 & 2030
6.3. Hematuria Treatment Market by Region: Key Takeaways
6.4. North America
- 6.4.1. U.S.
  - 6.4.1.1. Key country dynamics
  - 6.4.1.2. Regulatory framework/reimbursement structure
  - 6.4.1.3. Competitive scenario
  - 6.4.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
- 6.4.2. Canada
  - 6.4.2.1. Key country dynamics
  - 6.4.2.2. Regulatory framework/reimbursement structure
  - 6.4.2.3. Competitive scenario
  - 6.4.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
6.5. Europe
- 6.5.1. Germany
  - 6.5.1.1. Key country dynamics
  - 6.5.1.2. Regulatory framework/reimbursement structure
  - 6.5.1.3. Competitive scenario
  - 6.5.1.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
- 6.5.2. UK
  - 6.5.2.1. Key country dynamics
  - 6.5.2.2. Regulatory framework/reimbursement structure
  - 6.5.2.3. Competitive scenario
  - 6.5.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
- 6.5.3. France
  - 6.5.3.1. Key country dynamics
  - 6.5.3.2. Regulatory framework/reimbursement structure
  - 6.5.3.3. Competitive scenario
  - 6.5.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
- 6.5.4. Italy
  - 6.5.4.1. Key country dynamics
  - 6.5.4.2. Regulatory framework/reimbursement structure
  - 6.5.4.3. Competitive scenario
  - 6.5.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
- 6.5.5. Spain
  - 6.5.5.1. Key country dynamics
  - 6.5.5.2. Regulatory framework/reimbursement structure
  - 6.5.5.3. Competitive scenario
  - 6.5.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
- 6.5.6. Denmark
  - 6.5.6.1. Key country dynamics
  - 6.5.6.2. Regulatory framework/reimbursement structure
  - 6.5.6.3. Competitive scenario
  - 6.5.6.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
- 6.5.7. Sweden
  - 6.5.7.1. Key country dynamics
  - 6.5.7.2. Regulatory framework/reimbursement structure
  - 6.5.7.3. Competitive scenario
  - 6.5.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
- 6.5.8. Norway
  - 6.5.8.1. Key country dynamics
  - 6.5.8.2. Regulatory framework/reimbursement structure
  - 6.5.8.3. Competitive scenario
  - 6.5.8.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
6.6. Asia Pacific
- 6.6.1. Japan
  - 6.6.1.1. Key country dynamics
  - 6.6.1.2. Regulatory framework/reimbursement structure
  - 6.6.1.3. Competitive scenario
  - 6.6.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
- 6.6.2. China
  - 6.6.2.1. Key country dynamics
  - 6.6.2.2. Regulatory framework/reimbursement structure
  - 6.6.2.3. Competitive scenario
  - 6.6.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
- 6.6.3. India
  - 6.6.3.1. Key country dynamics
  - 6.6.3.2. Regulatory framework/reimbursement structure
  - 6.6.3.3. Competitive scenario
  - 6.6.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
- 6.6.4. South Korea
  - 6.6.4.1. Key country dynamics
  - 6.6.4.2. Regulatory framework/reimbursement structure
  - 6.6.4.3. Competitive scenario
  - 6.6.4.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
- 6.6.5. Australia
  - 6.6.5.1. Key country dynamics
  - 6.6.5.2. Regulatory framework/reimbursement structure
  - 6.6.5.3. Competitive scenario
  - 6.6.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
- 6.6.6. Thailand
  - 6.6.6.1. Key country dynamics
  - 6.6.6.2. Regulatory framework/reimbursement structure
  - 6.6.6.3. Competitive scenario
  - 6.6.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
6.7. Latin America
- 6.7.1. Brazil
  - 6.7.1.1. Key country dynamics
  - 6.7.1.2. Regulatory framework/reimbursement structure
  - 6.7.1.3. Competitive scenario
  - 6.7.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
- 6.7.2. Mexico
  - 6.7.2.1. Key country dynamics
  - 6.7.2.2. Regulatory framework/reimbursement structure
  - 6.7.2.3. Competitive scenario
  - 6.7.2.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
- 6.7.3. Argentina
  - 6.7.3.1. Key country dynamics
  - 6.7.3.2. Regulatory framework/reimbursement structure
  - 6.7.3.3. Competitive scenario
  - 6.7.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
6.8. MEA
- 6.8.1. South Africa
  - 6.8.1.1. Key country dynamics
  - 6.8.1.2. Regulatory framework/reimbursement structure
  - 6.8.1.3. Competitive scenario
  - 6.8.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
- 6.8.2. Saudi Arabia
  - 6.8.2.1. Key country dynamics
  - 6.8.2.2. Regulatory framework/reimbursement structure
  - 6.8.2.3. Competitive scenario
  - 6.8.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
- 6.8.3. UAE
  - 6.8.3.1. Key country dynamics
  - 6.8.3.2. Regulatory framework/reimbursement structure
  - 6.8.3.3. Competitive scenario
  - 6.8.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
- 6.8.4. Kuwait
  - 6.8.4.1. Key country dynamics
  - 6.8.4.2. Regulatory framework/reimbursement structure
  - 6.8.4.3. Competitive scenario
  - 6.8.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Competitive Landscape

7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
- 7.3.1. Key company heat map analysis, 2024
7.4. Company Profiles
- 7.4.1. AstraZeneca
  - 7.4.1.1. Company overview
  - 7.4.1.2. Financial performance
  - 7.4.1.3. Product benchmarking
  - 7.4.1.4. Strategic initiatives
- 7.4.2. Bristol-Myers Squibb Company
  - 7.4.2.1. Company overview
  - 7.4.2.2. Financial performance
  - 7.4.2.3. Product benchmarking
  - 7.4.2.4. Strategic initiatives
- 7.4.3. F. Hoffmann-La Roche Ltd.
  - 7.4.3.1. Company overview
  - 7.4.3.2. Financial performance
  - 7.4.3.3. Product benchmarking
  - 7.4.3.4. Strategic initiatives
- 7.4.4. Johnson & Johnson and its affiliates
  - 7.4.4.1. Company overview
  - 7.4.4.2. Financial performance
  - 7.4.4.3. Product benchmarking
  - 7.4.4.4. Strategic initiatives
- 7.4.5. Merck & Co., Inc.
  - 7.4.5.1. Company overview
  - 7.4.5.2. Financial performance
  - 7.4.5.3. Product benchmarking
  - 7.4.5.4. Strategic initiatives
- 7.4.6. Novartis AG
  - 7.4.6.1. Company overview
  - 7.4.6.2. Financial performance
  - 7.4.6.3. Product benchmarking
  - 7.4.6.4. Strategic initiatives
- 7.4.7. Pfizer Inc.
  - 7.4.7.1. Company overview
  - 7.4.7.2. Financial performance
  - 7.4.7.3. Product benchmarking
  - 7.4.7.4. Strategic initiatives
- 7.4.8. Sun Pharmaceutical Industries Ltd.
  - 7.4.8.1. Company overview
  - 7.4.8.2. Financial performance
  - 7.4.8.3. Product benchmarking
  - 7.4.8.4. Strategic initiativesa

한글목차

혈뇨 치료 시장 요약

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 혈뇨 치료 시장의 변수, 동향, 범위

제4장 혈뇨 치료 시장 : 치료 유형별 추정 및 동향 분석

제5장 혈뇨 치료 시장 : 유형별 추정 및 동향 분석

제6장 혈뇨 치료 시장 : 지역별 추정 및 동향 분석